News

BOSTON, MA – June 23, 2021

Bulfinch today announced that an affiliate of the Company has completed the acquisition of 804 Huntington Avenue, Mission Hill, Boston MA. Michael Greeley, Senior Managing Director of Newmark’s Medical-Academic Practice Group lead Newmark’s team in the representation of the seller.

Bulfinch is looking forward to working with all the project stakeholders and community partners, including Mission Hill Neighborhood Housing Services and Roxbury Tenants of Harvard, to create a state-of-the-art medical, office and life science building as well as much needed housing. The proposed development is anticipated to include a meaningful component of medical, office and lab space with additional ground floor retail. Bulfinch is working with project stakeholders and the community groups to incorporate housing within the project which will include an affordable component.

The property is strategically located in the Longwood Medical Area (LMA) in close proximity to Stop & Shop, Walgreens, Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Mass Eye and Ear Longwood along with major high education research institutions including Harvard Medical School. The property is also conveniently located between the Green Line’s Mission Park and Fenwood Road MBTA stops along with multiple bus stop locations creating a highly accessibly destination.

“804 Huntington’s extremely desirable location in the Longwood Medical Area and its proximity to major hospitals, research institutions and public transportation made the asset an excellent investment and addition to our diversified portfolio of properties in Greater Boston,” said Eric Schlager, CEO of Bulfinch. “We are excited to collaborate with the community to create a development that will not only contribute to Boston’s ground-breaking research and discovery but also enhance the neighborhood with proposed new retail and anticipated housing opportunities.”

The acquisition adds to Bulfinch’s growing portfolio in Brookline, Cambridge, Boston and Chestnut Hill and is consistent with the firm’s vision of acquiring and developing premier medical and life science properties in Boston’s core markets.